In addition, in the H292 treatment study CX-2009 has demonstrated tumor reduction similar to its parental ADC version, thus supporting the tumor accumulation data generated with 89Zr labeled constructs and, thereby, the PDC concept as tumor targeting ADC pro-drug approach (Figure 8). The gene discussed is PDC; the disease is neoplasm.